TRITACE 5 TABLET 5 mg

מדינה: סינגפור

שפה: אנגלית

מקור: HSA (Health Sciences Authority)

מרכיב פעיל:

RAMIPRIL

זמין מ:

SANOFI-AVENTIS SINGAPORE PTE. LTD.

קוד ATC:

C09AA05

כמות:

5 mg

טופס פרצבטיות:

TABLET

הרכב:

RAMIPRIL 5 mg

מסלול נתינה (של תרופות):

ORAL

סוג מרשם:

Prescription Only

תוצרת:

SANOFI S.r.l.

מצב אישור:

ACTIVE

תאריך אישור:

1997-12-22

עלון מידע

This package insert is continually updated: please read carefully 
before using a new pack!

TRITACE
®
 1.25 TABLETS 
TRITACE
®
 2.5 TABLETS 
TRITACE
®
 5 TABLETS 
TRITACE
®
 10 TABLETS 
_Ramipril _
_ _
[SANOFI LOGO] 

COMPOSITION 
Each tablet Tritace
®
 1.25 contains, as active ingredient, 1.25 mg ramipril. 
Each tablet Tritace
®
 2.5 contains, as active ingredient, 2.5 mg ramipril. 
Each tablet Tritace
®
 5 contains, as active ingredient, 5 mg ramipril. 
Each tablet Tritace
®
 10 contains, as active ingredient, 10 mg ramipril. 
Excipients: Methylhydroxypropylcellulose, pregelatinized maize
starch, 
microcrystalline cellulose, sodium stearyl fumarate, yellow ferric
oxide 
(Tritace 2.5 only), red ferric oxide (Tritace 5 only). 
Not all presentation is available in all countries. 

PROPERTIES 
Ramiprilat, the active metabolite of ramipril, is a potent and
long-acting angiotensin converting enzyme (ACE) inhibitor. 
Administration of Tritace results in a vasodilatation and,
especially in hypertensive patients, in a reduction of blood
pressure. 
The blood-pressure-lowering effect of a single dose occurs within 1
– 2 hours after intake, reaching its peak within 3 - 6 hours, and 
usually lasts 24 hours. 
Tritace is also effective in the treatment of congestive heart
failure. 
Further, in patients demonstrating clinical signs of congestive heart
failure after an acute myocardial infarction, Tritace has been 
shown to decrease the mortality risk (including the risks of sudden
death, of progression to severe/resistant heart failure and of 
failure-related hospitalisation). 
Tritace, when administered on a preventive basis,
significantly reduces the incidence of myocardial infarction, stroke
or 
cardiovascular deaths in patients with an
increased cardiovascular risk attributable to vascular diseases
(such as manifest coronary 
heart disease, or a history of stroke or of peripheral vascular
disease) or to diabetes mellitus with at l

מאפייני מוצר

SG/TRI/0322/CCDS V16-18
1
This package insert is continually updated: please read carefully
before using a new pack!
TRITACE
® 2.5 TABLETS
TRITACE
® 5 TABLETS
_Ramipril _
_ _
COMPOSITION
Each tablet Tritace
®
2.5 contains, as active ingredient, 2.5 mg ramipril.
Each tablet Tritace
®
5 contains, as active ingredient, 5 mg ramipril.
Excipients: Methylhydroxypropylcellulose, pregelatinized maize starch,
microcrystalline cellulose, sodium stearyl fumarate, yellow ferric
oxide
(Tritace 2.5 only), red ferric oxide (Tritace 5 only).
Not all presentation is available in all countries.
PROPERTIES
Ramiprilat, the active metabolite of ramipril, is a potent and
long-acting angiotensin converting enzyme (ACE) inhibitor.
Administration of Tritace results in a vasodilatation and, especially
in hypertensive patients, in a reduction of blood pressure.
The blood-pressure-lowering effect of a single dose occurs within 1
– 2 hours after intake, reaching its peak within 3 - 6 hours, and
usually lasts 24 hours.
Tritace is also effective in the treatment of congestive heart
failure.
Further, in patients demonstrating clinical signs of congestive heart
failure after an acute myocardial infarction, Tritace has been
shown to decrease the mortality risk (including the risks of sudden
death, of progression to severe/resistant heart failure and of
failure-related hospitalisation).
Tritace,
when
administered
on
a
preventive
basis,
significantly
reduces
the
incidence
of
myocardial
infarction,
stroke
or
cardiovascular deaths in patients with an increased cardiovascular
risk attributable to vascular diseases (such as manifest coronary
heart disease, or a history of stroke or of peripheral vascular
disease) or to diabetes mellitus with at least one additional risk
factor
(microalbuminuria,
hypertension,
elevated
total
cholesterol
levels,
low
high-density
lipoprotein
cholesterol
levels,
smoking).
Moreover, it reduces total mortality as well as the need for
revascularisations, and delays the start and the progression of
congestive
heart failu